AzTrials
AzTrials

HyperbilirubinemiaNCT07409194

The Effect of Acupressure on Hyperbilirubinemia in Newborns: A Randomized Controlled Trial

A study testing Acupressure in people with Hyperbilirubinemia, run by Yuzuncu Yil University at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study is a randomized controlled trial conducted to evaluate the effect of acupressure application on hyperbilirubinemia in newborns. The study examined the effect of regular acupressure applications to specific points on serum bilirubin levels in newborns at risk of developing physiological jaundice in the first… Read more about this study

Who is it for?
Ages 38 weeks to 42 months
Conditions the study is for
Hyperbilirubinemia
What is being tested?
Acupressure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
1 siteTurkey (Türkiye)
Study dates
5 May 2025to 15 May 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 38 weeks to 42 months
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Gestational age ≥38 weeks
  • Diagnosed with neonatal hyperbilirubinemia
  • Hospitalized in the neonatal unit for at least 24 hours
  • Birth weight ≥2500 g
  • Written informed consent obtained from parents

Who cannot join

  • Preterm newborns
  • Congenital metabolic disease or congenital anomalies
  • Hemodynamically unstable newborns
  • Newborns whose parents did not provide consent
  • Newborns with any condition preventing acupressure application

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Van Yuzuncu Yil University

    Van, 65100

Other trials in Turkey (Türkiye)

About this study

This study is a randomized controlled trial conducted to evaluate the effect of acupressure application on hyperbilirubinemia in newborns. The study examined the effect of regular acupressure applications to specific points on serum bilirubin levels in newborns at risk of developing physiological jaundice in the first days of life. By comparing bilirubin levels between the experimental and control groups, the potential benefits of acupressure in reducing the severity of jaundice and supporting bilirubin metabolism were investigated. The findings suggest that acupressure can be used as a complementary method in neonatal care.

Read the detailed description

One of the most common problems encountered in the neonatal period is neonatal jaundice, which develops due to an increase in indirect bilirubin (Özdemir and Yılmaz, 2019). Jaundice (hyperbilirubinemia) is defined as the yellowing of the skin and the whites of the eyes due to the accumulation of bilirubin in the skin and mucous membranes of newborns (Kılıç and Yılmaz, 2021). Jaundice is a common condition seen in 60% of term infants and more than 80% of preterm infants (Muniyappa and Kelley, 2020). Hyperbilirubinemia (HB), which is frequently seen in newborns, especially in the indirect form, is a mild health problem in most cases (Olcar, 2019; Yılmaz, 2019). HB in newborns usually progresses cephalocaudally (from head to toe); it starts in the face and spreads to the body as serum bilirubin levels increase (Turkish Neonatology Association [TND], 2022). Symptoms such as lethargy and feeding difficulties may occur in infants with severe HB. If not treated promptly, serious neurological complications such as kernicterus may occur. Early diagnosis, close monitoring, and treatment are vital to prevent potential damage in newborns (Muniyappa and Kelley, 2020).

Various treatment methods have been developed to reduce bilirubin levels. Among these methods, the most commonly used are blood exchange, phototherapy, and drug treatments (Garg et al., 2019; Kılıç and Yılmaz, 2021). To support neonatal HB treatment, studies evaluating the effectiveness of non-pharmacological and complementary applications, in addition to pharmacological methods, have also been conducted (Öztürk, 2025; Coşkun and Karakoç., 2025; Wu et al., 2022).

Acupressure is a complementary treatment method that aims to control symptoms by applying pressure to specific points on the meridians (İskender and Çalışkan, 2020). During the application, sensitive pressure is applied to specific points on the body using the hands and fingers, and in some cases, special tools; this aims to regulate energy flow and support the body's natural healing processes (Dincer et al., 2022; Harris et al., 2020). These stimuli, applied through touch, can activate receptors in the skin of infants with HB and be transmitted to the brain centers via reflex pathways. This can stimulate the parasympathetic nervous system and the vagus nerve, accelerating bowel movements, contributing to the regulation of the digestive system, and helping to expel meconium more quickly (Roth and Sullivan, 2006). In this regard, it is crucial to correctly identify the appropriate acupressure points during the treatment process (Bayraktar, 2023).

The application of acupressure has been used in various clinical settings in the neonatal and pediatric populations, and its effects on different physiological outcomes have been investigated. The effects of acupressure on pain (Altıntaş, 2023; Oğul, 2023; Özkan and Balcı, 2018), infantile colic (Özgören, 2021), and chemotherapy-induced nausea and vomiting (Balcı, 2018) in the pediatric group have been examined in various studies. However, it has been determined that studies evaluating the effect of acupressure on HB in newborns (Wu et al., 2022) are quite limited. Therefore, the aim of this study is to evaluate the effect of acupressure applied to newborns on HB. In this context, the potential contributions of acupressure to reducing serum bilirubin levels and supporting the treatment process will be examined, and it is aimed that the findings will provide scientific evidence regarding the effectiveness of acupressure as a complementary approach in the management of hyperbilirubinemia and guide clinical practice.

Being tested
Acupressure
Medical subject headings
Hyperbilirubinemia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AcupressureBehavioural

    Acupressure intervention

Study groups in NCT07409194
Study groupRoleWhat they receive
Acupressure GroupExperimentalNewborns assigned to the intervention group receive standard acupressure at predetermined acupuncture points (ST36 - Zusanli and KI1 - Yongquan) by a trained practitioner 0 and 12 hours after birth. Each session lasts approximately 4 minutes. Total serum bilirubin levels are measured 24 hours after birth. All newborns continue to receive routine newborn care and feeding according to the unit protocol.
Receives: Behavioral: Acupressure
Control GroupNo interventionNewborns assigned to the control group receive routine neonatal care and feeding according to unit protocol without any acupressure intervention. Total serum bilirubin levels are measured at the 24th hour of life.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Total Serum Bilirubin Level

    Measurement of total serum bilirubin level to evaluate the effect of acupressure on neonatal hyperbilirubinemia.

    Measured: 24 hours after birth

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Feb 2026
  2. Study start5 May 2025
  3. Primary completion5 Feb 2026
  4. Study completion15 May 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Randomised
Intervention model
Sequential
Masking
Single blind
Who is masked
Participant
Enrolment
60 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07409194
Sponsor's protocol ID
2025/05-14
Status last verified
Oct 2026
First submitted
6 Feb 2026
Last updated
27 Oct 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Acupressure in people with Hyperbilirubinemia, run by Yuzuncu Yil University at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 27 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Total Serum Bilirubin Level (time frame: 24 hours after birth). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Oct 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in